Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2021-02-16 Earnings Release
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Vivozon Healthcare) disclosing a significant change in financial structure (30% or more change in revenue or profit/loss). This type of disclosure is a standard regulatory requirement in Korea for listed companies to report preliminary financial results before the final audit is completed. It provides key financial highlights (revenue, operating profit, net income) and reasons for the variance. It fits the definition of an Earnings Release (ER) as it is an initial announcement of financial results. FY 2020
2021-02-16 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details changes in share ownership by a specific entity (Korea Fixed-income Investment Advisory Co., Ltd.) in a listed company (Vivozon Healthcare). This falls under the category of Major Shareholding Notification.
2021-02-10 Korean
전환청구권행사(제9, 13회차)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Vivozon Healthcare regarding the exercise of conversion rights (convertible bonds) into shares. This type of disclosure, which details changes in capital structure due to the conversion of debt into equity, falls under the category of share issuance or capital changes. Given the specific nature of convertible bond exercises, it is classified as a capital change/share issue announcement.
2021-02-04 Korean
[기재정정]전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from a Korean company (Vivozon Healthcare) regarding the exercise of conversion rights (convertible bonds into shares). This type of corporate action, involving the issuance of new shares through the conversion of debt, falls under the category of capital changes or share issues. Given the specific nature of the filing (conversion of convertible bonds), it is best classified as a share issue/capital change announcement.
2021-01-27 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea used to disclose significant changes in share ownership (crossing the 5% threshold or subsequent changes). This corresponds to the 'Major Shareholding Notification' category.
2021-01-26 Korean
전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a formal notification regarding the exercise of conversion rights (전환청구권행사) for convertible bonds into shares. It details the number of shares issued, the conversion price, and the remaining balance of convertible bonds. This type of corporate action, which involves the issuance of new shares resulting from debt conversion, falls under the category of capital changes or share issues.
2021-01-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.